期刊文献+

宫颈液基细胞学检查结果与宫颈癌前病变高危型HPV感染的关系分析 被引量:1

下载PDF
导出
摘要 目的探究宫颈液基细胞学检查(TCT)结果与宫颈癌前病变高危型HPV(HR-HPV)感染的关系。方法选取2019年6月—2021年6月肇庆市中医院收治的已确诊为宫颈癌前病变的78例患者作为研究对象,均行HR-HPV检查和TCT检查。分析患者的HR-HPV阳性检出率及具体分型,并根据其是否感染高危型HPV分为感染组和非感染组。收集患者的基线资料及TCT检查结果,采用Logistic多因素回归模型分析TCT检查结果与宫颈癌前病变HR-HPV感染的关系。结果78例宫颈癌前病变患者中,HR-HPV感染的阳性率为58.97%,其中HPV16,18,31,38,58型及其他型的阳性率分别为24.36%,15.38%,7.69%,3.85%,5.13%及2.56%。单因素分析结果显示,TCT检查结果细胞学病变程度、生育史、阴道炎症史、性伴侣个数、阴道不规则出血是宫颈癌前病变患者HR-HPV感染的影响因素(P<0.05)。Logistic回归分析结果显示,TCT检查结果细胞学病变程度高、有阴道炎症史、性伴侣个数多是宫颈癌前病变患者HR-HPV感染的独立危险因素(P<0.05)。结论宫颈癌前病变患者高危型HPV感染率较高,以HPV16,18感染为主,其中TCT检查结果细胞学病变程度越高,患者感染HR-HPV的概率越大。
机构地区 肇庆市中医院
出处 《基层医学论坛》 2023年第17期63-65,共3页 The Medical Forum
  • 相关文献

参考文献8

二级参考文献71

  • 1Klinkhamer PJ,Meerding WJ,Rosier PF,et al.Liquid-based cervical cytology[J].Cancer,2003,99 (5):263-271.
  • 2Nuovo J,Melnikow J,Howell LP.New tests for cervical cancer screening[J].Am Fam Physician,2001,64(5):729-730.
  • 3Herbest AL.The Bethesda system for reporting cervical/vaginal cytological diagnoses[J].Clin Obstet Gynecol,1992,35 (1):22-27.
  • 4Biscotti CV,Dawson AE,Dziura B,et al.Assisted primary screening using the automated ThinPrep Imaging System[J].Am J Clin Pathol,2005,123(2):281-287.
  • 5Pan Q,Belinson JL,Li L,et al.A thin-layer,liquid-based pap test for mass screening in an area of China with a high incidence of cervical carcinoma:a cross-sectional,comparative study[J].Acta Cytol,2003,47(1):45-50.
  • 6Kulasingam SL,Hughes JP,Kiviat NB,et al.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities:comparison of sensitivity,specificity,and frequency of referral[J].JAMA,2002,288(14):1749-1757.
  • 7Tao X, Gfiffith CC, Zhou X, et al. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China [ J ]. Cancer Cytopathol, 2015,123 (7) :421-427.
  • 8Yang L, He Z, Huang XY, et al. Prevalence of human papilloma- virus and the correlation of HPV infection with cervical disease in Weihai, China[ J]. Eur J Gynaecol Oncol, 2015,36( 1 ) :73-77.
  • 9Campos NG, Castle PE, Wright TC Jr, et al. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage [J]. Int J Cancer, 2015,137(9) :2208-2219.
  • 10Wang JL, Yang YZ, Dong WW, et al. Application of human pap- illomavirus in screening for cervical cancer and precancerous le- sions [ J ]. Asian Pac J Cancer Prey, 2013,14 (5) :2979-2982.

共引文献232

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部